未登录

Y

Yisheng Pan

北京大学

H指数:20

被引数:1,347

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prospects of probiotic Escherichia coli Nissle 1917 in the treatment of septic shock

益生菌大肠杆菌Nissle 1917在脓毒性休克治疗中的前景

IF2.7

2024-12-010

PRE

Case report: a rare case of duodenal metastasis of endometrial carcinosarcoma

FRONTIERS IN ONCOLOGY

IF3.3

2024-10-150

OAAI

Obesity and overweight are associated with worse survival in early-onset colorectal cancer: A critical analysis of sample selection criteria

IF2.7

2024-10-010

PRE

Escherichia coli Nissle 1917 Protects against Sepsis-Induced Intestinal Damage by Regulating the SCFA/GPRs Signaling Pathway

IF4.2

2024-08-082

OAAI

A commentary on 'Circulating metabolic markers after surgery identify patients at risk for severe postoperative complications: a prospective cohort study in colorectal cancers'

INTERNATIONAL JOURNAL OF SURGERY

IF10.1

2024-08-010

OAAI

Letter to the Editor for the article 'Pharmacologic prevention and therapy of postoperative paralytic ileus after gastrointestinal cancer surgery - systematic review and meta-analysis'

INTERNATIONAL JOURNAL OF SURGERY

IF10.1

2024-08-010

OAAI

The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma (vol 42, 44, 2023)

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IF12.8

2024-07-200

OAAI

YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis

IF5.1

2024-05-233

OAAI

The Surveillance for Presumed BD-IPMN of the Pancreas

GASTROENTEROLOGY

IF25.1

2024-05-012

PRE

Treatment with S-adenosylmethionine ameliorates irinotecan-induced intestinal barrier dysfunction and intestinal microbial disorder in mice (vol 216, 115752, 2023)

BIOCHEMICAL PHARMACOLOGY

IF5.6

2023-12-010

PRE

Predictors and outcomes of recurrent retroperitoneal liposarcoma: new insights into its recurrence patterns

IF3.4

2023-11-083

OAAI

The influence of invasive procedures on acute HBV and HCV infections

JOURNAL OF HEPATOLOGY

IF33

2023-11-010

OA

Treatment with S-adenosylmethionine ameliorates irinotecan-induced intestinal barrier dysfunction and intestinal microbial disorder in mice

BIOCHEMICAL PHARMACOLOGY

IF5.6

2023-10-015

OAAI

Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update

ANNALS OF ONCOLOGY

IF65.4

2023-10-010

OA

Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer

中性粒细胞作为肿瘤免疫的关键调节因子，限制肝癌的免疫检查点阻断

CANCER BIOLOGY & MEDICINE

IF8.4

2023-05-1311

OAAI

The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IF12.8

2023-02-098

OAAI

CBS-H2S axis preserves the intestinal barrier function by inhibiting COX-2 through sulfhydrating human antigen R in colitis

CBS-H2S轴通过硫酸化人抗原R抑制COX-2来维持肠屏障功能

JOURNAL OF ADVANCED RESEARCH

IF13

2023-02-015

OAAI

PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway

IF6.4

2022-03-0723

OAAI

Stratified Prognostic Value of Pathological Response to Preoperative Treatment in yp II/III Rectal Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2021-12-162

OAAI

Methylome profiling identifies TCHH methylation in CfDNA as a noninvasive marker of liver metastasis in colorectal cancer

甲基化组分析将CfDNA中的TCHH甲基化鉴定为结直肠癌肝转移的非侵入性标志物

IF4.2

2021-06-104

PRE